MacroGenics Balance Sheet Health
Financial Health criteria checks 5/6
MacroGenics has a total shareholder equity of $46.6M and total debt of $70.3M, which brings its debt-to-equity ratio to 150.7%. Its total assets and total liabilities are $245.4M and $198.8M respectively.
Key information
150.71%
Debt to equity ratio
US$70.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$176.49m |
| Equity | US$46.62m |
| Total liabilities | US$198.80m |
| Total assets | US$245.42m |
Recent financial health updates
Recent updates
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Sep 08
MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets
Sep 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Jul 24Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
May 21MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Apr 14
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Feb 28MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Feb 27MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Dec 05Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Financial Position Analysis
Short Term Liabilities: MGNX's short term assets ($204.9M) exceed its short term liabilities ($39.0M).
Long Term Liabilities: MGNX's short term assets ($204.9M) exceed its long term liabilities ($159.8M).
Debt to Equity History and Analysis
Debt Level: MGNX has more cash than its total debt.
Reducing Debt: MGNX's debt to equity ratio has increased from 0% to 150.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGNX has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 12.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/11 21:36 |
| End of Day Share Price | 2025/09/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |